Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
PRNewsWire
·
2026-04-30
·
via The Tech Buzz - Press Releases
Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1 2026 EPS increased by 170% to $8.26 on a r
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。
